Amotiv Limited

Healthcare CA AOV

NoneCAD
0.00(0%)

Last update at 2026-06-22T21:00:32.771694Z

Day Range

LowHigh

52 Week Range

5.507.74

LowHigh

Fundamentals

Previous Close 9.27
Market Cap576.83M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA49.78M
Revenue TTM332.21M
Revenue Per Share TTM3.17
Gross Profit TTM 138.06M
Diluted EPS TTM-0.16

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-6.70200M	2.05M	-21.98800M	-43.96000M	6.69M
Minority interest	-	-	-	-	0.00000M
Net income	-5.37400M	4.33M	-16.83500M	-29.89200M	15.68M
Selling general administrative	124.11M	99.35M	83.69M	40.15M	37.16M
Selling and marketing expenses	-	-	-	48.47M	37.22M
Gross profit	207.70M	174.41M	152.65M	138.06M	115.41M
Reconciled depreciation	-	-	50.40M	62.62M	47.91M
Ebit	-	-	-	-2.40300M	-5.32200M
Ebitda	-	-	-	60.22M	42.59M
Depreciation and amortization	-	-	-	62.62M	47.91M
Non operating income net other	-	-	-	-	-
Operating income	-2.35000M	7.40M	0.41M	-2.40300M	-5.32200M
Other operating expenses	-	-	-	310.62M	256.31M
Interest expense	-	-	12.49M	6.60M	3.62M
Tax provision	-1.32800M	-2.28000M	-5.15300M	-14.06800M	-8.98500M
Interest income	4.70M	16.23M	28.50M	15.76M	14.04M
Net interest income	-	-	0.09M	4.03M	3.76M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-14.06800M	-8.98500M
Total revenue	450.09M	371.30M	328.20M	293.56M	243.48M
Total operating expenses	452.44M	-	321.83M	155.12M	128.24M
Cost of revenue	242.38M	196.90M	175.55M	155.50M	128.07M
Total other income expense net	-	-	-28.44500M	-41.55700M	12.01M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-	-	-16.83500M	-29.89200M	15.68M
Net income applicable to common shares	-5.37400M	4.33M	-16.83500M	-29.89200M	15.68M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	1046.30M	963.80M	945.49M	1054.84M	991.89M
Intangible assets	379.51M	283.61M	289.96M	338.78M	350.30M
Earning assets	-	-	-	-	-
Other current assets	-	0.00000M	-	1.70M	4.51M
Total liab	279.03M	168.69M	198.62M	228.98M	149.87M
Total stockholder equity	767.27M	795.11M	746.87M	825.86M	842.02M
Deferred long term liab	-	-	-	-	-
Other current liab	-	-	1.05M	15.01M	11.72M
Common stock	530.14M	534.27M	-	599.05M	628.85M
Capital stock	-	-	540.05M	599.05M	628.85M
Retained earnings	148.94M	154.91M	150.89M	161.75M	191.65M
Other liab	-	-	-	-	31.89M
Good will	89.98M	86.48M	79.84M	82.27M	75.40M
Other assets	35.80M	28.46M	-	15.60M	57.05M
Cash	71.09M	74.99M	58.76M	71.68M	85.96M
Cash and equivalents	5.35M	5.11M	-	0.30M	9.03M
Total current liabilities	165.26M	111.25M	114.03M	141.32M	105.30M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	3.10M	6.02M	-45.00500M
Short term debt	0.00000M	0.00000M	-	20.25M	28.28M
Short long term debt	-	-	17.85M	17.67M	26.66M
Short long term debt total	-	-	-	77.70M	40.96M
Other stockholder equity	59.58M	79.99M	-	23.78M	21.89M
Property plant equipment	21.93M	20.02M	-	22.63M	29.94M
Total current assets	394.83M	396.81M	365.12M	395.62M	307.32M
Long term investments	-	-	120.02M	158.02M	178.95M
Net tangible assets	-	-	-	-	416.32M
Short term investments	37.78M	83.02M	111.41M	119.54M	77.03M
Net receivables	127.78M	105.20M	88.72M	110.20M	67.41M
Long term debt	51.16M	25.90M	44.02M	52.40M	9.27M
Inventory	135.87M	102.70M	91.83M	92.49M	72.40M
Accounts payable	-	-	85.37M	106.06M	65.31M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	41.27M	-0.37600M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	48.20M	47.93M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	-	-	580.38M	659.22M	684.57M
Capital lease obligations	-	-	7.22M	7.63M	5.03M
Long term debt total	57.78M	29.33M	-	57.45M	12.68M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	-	29.34M	-63.07900M	85.29M
Change to liabilities	-	-	-	0.00000M	11.46M
Total cashflows from investing activities	-75.15800M	16.96M	29.34M	-63.07900M	-105.27900M
Net borrowings	-	-	-	-	-14.19200M
Total cash from financing activities	5.41M	-33.54000M	-81.00200M	1.76M	-78.31000M
Change to operating activities	-	-	-	-5.41300M	2.00M
Net income	-5.37400M	4.33M	-16.83500M	-29.89200M	15.68M
Change in cash	-3.65700M	21.34M	-12.91800M	-14.28400M	-143.62900M
Begin period cash flow	-	58.76M	71.68M	85.96M	229.59M
End period cash flow	-	-	58.76M	71.68M	85.96M
Total cash from operating activities	68.96M	36.28M	35.94M	40.48M	44.62M
Issuance of capital stock	-	-	-	-	-
Depreciation	56.57M	53.11M	50.40M	62.62M	47.91M
Other cashflows from investing activities	-41.46400M	48.44M	39.30M	-37.26300M	30.93M
Dividends paid	-	-	0.00000M	0.00000M	-
Change to inventory	-	-	0.70M	-11.42800M	-17.18800M
Change to account receivables	-	-	5.25M	-26.41800M	8.59M
Sale purchase of stock	-6.35200M	-8.29000M	-53.47900M	-30.06900M	-64.41500M
Other cashflows from financing activities	-6.86800M	-7.19900M	-9.49900M	52.12M	9.72M
Change to netincome	-	-	-	17.74M	-16.96300M
Capital expenditures	33.69M	31.47M	9.96M	25.82M	224.18M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	1.89M	-19.62400M	-26.89800M	-9.98900M	0.63M
Stock based compensation	-	-	2.33M	1.89M	3.04M
Other non cash items	-	-	10.30M	32.98M	-15.00800M
Free cash flow	-	-	25.98M	14.66M	-179.56500M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
AOV Amotiv Limited	- -%	-	-	263.16	1.76	0.77	1.45	11.63
CURA Curaleaf Holdings Inc.	-0.32 2.28%	13.74	-	138.89	2.57	3.14	2.47	13.10
BHC Bausch Health Companies Inc	0.05 0.76%	6.62	13.98	1.35	0.28	18.74	2.12	6.84
CRON Cronos Group Inc	-0.06 1.57%	3.75	-	32.15	9.80	0.95	1.47	1.90
TLRY Tilray Inc	-0.21 3.12%	6.52	-	1000.00	1.28	0.53	1.08	-2.299

Reports Covered

View All

Profile

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Amotiv Limited

3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8

514-484-4483
https://www.gud-knight.com
Employees : 725

Key Executives

Name	Title	Year Born
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.	Executive Chairman	1969
Ms. Samira Sakhia BCom, CA, CPA, MBA	President, CEO & Director	1968
Mr. Arvind Utchanah	Chief Financial Officer	NA
Ms. Amal Khouri B.Sc., M.B.A.	Chief Business Officer	NA
Mr. Jeff Martens	Global Vice President of Commercial	NA
Mr. Stephani Saverio	Vice President of Business Development	NA
Mr. Leopoldo Bosano	Vice-President of Manufacturing & Operations	NA
Ms. Monica Percario	Global Vice President of Scientific Affairs	NA
Mr. Henrique Dias	Global Director of Marketing	NA
Ms. Susan Caroline Emblem	Global Vice President of Human Resources	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.